



Sebastián Duarte

Contact Information	<ul style="list-style-type: none">• Av Medrano 134 floor 6 Caba. Bs As. Argentina. Zip Code C1179AAB.• Phone 054 011 4983 1589.• Email: sebastianduarte@imoba.com.ar
Educación	<ul style="list-style-type: none">○• Provision 6677/10 ANMAT, LATAM Jun 2019• Good Clinical Practice, Eli Lilly 2019.• Data systems for research: Inform• Good Clinical Practice, The Global Healt Network, Oct 2019• Diploma in Good Practices in Biomedical Research. University of San Pablo.Tucumán. August 2020 to July 2021 (238 hours).
Current employment information	<ul style="list-style-type: none">• Investigaciones Médicas IMOBA SRL• Av. Medrano 134 floor 6 CABA• Data Entry from 2019 to present.

**Clinical studies in
the last 5 years**

- I8F-MC-GPGM Efficacy and safety of Ly3298176 once a week vs insulin glargine in patients with type 2 diabetes and high cardiovascular risk. From March 2018 to July 2021. Phase III. Eli Lilly. Data Entry.
- I8F-MC-GPGH: Phase 3 open-label, randomized study comparing the effect of LY3298176 vs titrated insulin Degludec on the glycemic control of pts. with type 2 diabetes. Eli Lilly. From July 2018 to April 2021. Phase III. Eli Lilly. Data Entry
- I8F-MC-GPGL: Randomized, open-label, phase 3 trial, comparing the efficiency and safety of Tirzepatide vs Semaglutide once a week as an add-on therapy to metformin in patients with type 2 DBT. Eli Lilly. From July 2019 to May 2021. Phase III. Eli Lilly. Data entry.
- FINEART s-HF-(Bayer) Multicenter, randomized, double-blind, placebo-controlled parallel group study to evaluate the efficacy and safety of finerenone in morbidity and mortality in patients with Heart Failure (NYHA II-IV) and fraction left ventricular ejection $\geq 40\%$ (LVEF $\geq 40\%$). Phase 3. Data Entry. From Oct 2020 to present.
- I8H-MC-BDCL A Phase 2 parallel, comparator- Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin- Native with Type 2 Diabetes Mellitus. Eli Lilly. Data entry. From Nov 2020 to present.
- I8F-MC-GPHM Efficacy and SAfefty of Tirzepatide Once Weekly vs Placebo after an intensive Lifestyle Program participants without Type 2 Diabetes who have Obesiy or are Overweight with weight- related Comorbidities: Randomized Double Blind, Placebo Controlled Trial. Data entry. From April 2021 to present.
- I8F-MC-GPHD Arandomized, phase 3, open label Trial comparing the effect of the addition of tirzepatide once weekly vs insulin lispro (U100)Three times daily in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin. Data entry. From Dec 2020 to present.

Signature:

Date:

